29 completed. 29 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 29 | Completed 29 |
| Phase 3 | 4 | Completed 4 |
| Phase 1 | 1 | Completed 1 |
Follow Thinness: new trials by email Literature Review of Thinness trials Research Report on Thinness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15 ponsegromab, Placebo for ponsegromab - Non-small Cell Lung Cancer, Pancreatic Cancer | Phase 2 | Completed | Pfizer | 187 | 2022-11-21 | 2026-06-03 |
| Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care. Mirtazapine, Megestrol - Cachexia; Cancer, Anorexia | Phase 2 | Completed | University of Sao Paulo | 52 | 2019-03-26 | 2023-07-07 |
| Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD) GSK2881078, Matching Placebo - Cachexia | Phase 2 | Completed | GlaxoSmithKline | 97 | 2018-02-28 | 2020-07-15 |
| Reformulated F75 Milk to Treat Severe Acute Malnutrition Standard F75 Milk, Modified F75 Milk - Malnutrition, Diarrhoea | Phase 2 / Phase 3 | Completed | University of Oxford | 842 | 2014-12-01 | 2016-04-14 |
| Impact of Nutritional Intervention in Indian Female Cancer Cachexia Patients Improved Atta, Nutritional counseling, Physical activity counseling - Cachexia, Cancer | Phase 2 | Completed | University of Westminster | 62 | 2013-12-01 | 2015-01-30 |
| BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia Placebo, BYM338 - Chronic Obstructive Pulmonary Disease (COPD) With Cachexia | Phase 2 | Completed | Novartis Pharmaceuticals | 67 | 2012-09-01 | 2016-05-03 |
| Complementary Food Supplements for Reducing Childhood Undernutrition Wheat Soy Blend (WSB++), Chickpea based complementary food supplement, Rice based complementary food supplement - Stunting, Wasting | Phase 2 / Phase 3 | Completed | Johns Hopkins Bloomberg School of Public Health | 5449 | 2012-09-01 | 2018-08-24 |
| Soy-Ready to Use Therapeutic Food (RUTF) in Severely Malnourished Children Soy-based RUTF (in double blind design) - Severe Acute Malnutrition, Severe Wasting | Phase 2 / Phase 3 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 260 | 2012-07-01 | 2017-09-25 |
| Effectiveness of Nutritional Products to Treat Moderate Acute Malnutrition A daily ration of 40 kcal/kg of body weight during 56 days - Wasting, Moderate Acute Malnutrition | Phase 2 | Completed | Centre for Food and Nutrition Research, Yaounde | 81 | 2012-02-01 | 2013-07-12 |
| Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas BYM338 active drug, Placebo - Cachexia | Phase 2 | Completed | Novartis Pharmaceuticals | 57 | 2011-08-01 | 2016-03-02 |
| A Clinical Study With MT-102 in Subjects With Cancer Cachexia MT-102 - Cancer Cachexia | Phase 2 | Completed | Akamis Bio | 87 | 2011-04-01 | 2014-09-10 |
| Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) Olanzapine - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 / Phase 3 | Completed | Charite University, Berlin, Germany | 40 | 2011-03-01 | 2024-02-14 |
| Individual Dose-escalated Bi-daily Subcutaneously (sc) Ghrelin in Cancer Cachexia: a Phase I/II Study ghrelin - Advanced Cancer, Cachexia | Phase 1 / Phase 2 | Completed | Cantonal Hospital of St. Gallen | 21 | 2009-06-01 | 2017-08-01 |
| Pilot Study of APD209 in Cancer Cachexia APD209 - Cancer-related Cachexia | Phase 2 | Completed | Acacia Pharma Ltd | 13 | 2009-03-01 | 2012-01-13 |
| Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia ALD518, Infusion of 0.9% Saline without ALD518 - NSCLC, Fatigue | Phase 2 | Completed | CSL Behring | 124 | 2008-09-01 | 2020-07-09 |
| SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD) Placebo comparator, SUN11031 20 μg/kg, SUN11031 40 μg/kg - Cachexia | Phase 2 | Completed | Daiichi Sankyo | 227 | 2008-05-15 | 2021-01-28 |
| Study of GTx-024 on Muscle Wasting (Cachexia) Cancer. GTx-024, Placebo - Cachexia | Phase 2 | Completed | GTx | 159 | 2007-05-01 | 2014-07-11 |
| Regimen for the Treatment of Cachexia in Subjects With NSCLC VT-122 low dose, VT-122 high dose - Cachexia | Phase 2 | Completed | Vicus Therapeutics | 37 | 2007-01-01 | 2013-01-30 |
| Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss RC-1291 HCl - Cancer Cachexia | Phase 2 | Completed | Helsinn Therapeutics (U.S.), Inc | 80 | 2005-06-01 | 2013-09-02 |
| Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL, Megestrol acetate oral suspension 40 mg/mL - HIV Infections, Cachexia | Phase 2 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 63 | 2004-12-01 | 2017-10-05 |
Showing 20 of 29. Sign in to see all of them.
Cachexia (29) · Anorexia (8) · Neoplasms (5) · HIV Infections (4) · Pulmonary Disease, Chronic Obstructive (4) · Acquired Immunodeficiency Syndrome (3) · Fatigue (3) · Pancreatic Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Emaciation (2) · HIV Wasting Syndrome (2) · Lung Neoplasms (2) · Malnutrition (2) · Muscular Atrophy (2)
Pathological Conditions, Signs and Symptoms (29) · Signs and Symptoms (29) · Body Weight (28) · Body Weight Changes (28) · Weight Loss (27) · Signs and Symptoms, Digestive (9) · Lung Diseases (8) · Respiratory Tract Diseases (8) · Pathologic Processes (7) · Disease Attributes (6) · Immune System Diseases (6) · Neoplasms by Site (6) · Nutrition Disorders (6) · Nutritional and Metabolic Diseases (6)
Megestrol Acetate (5) · Infliximab (2) · Cyproheptadine (1) · Etanercept (1) · GSK2881078 (1) · Gemcitabine (1) · Ghrelin (1) · Megestrol (1) · Mirtazapine (1) · Nutrition Assessment (1) · Olanzapine (1) · Physical Therapy Modalities (1) · Sodium Chloride (1) · Testosterone (1) · Thalidomide (1)
Novartis Pharmaceuticals (2) · Acacia Pharma Ltd (1) · Akamis Bio (1) · Bristol-Myers Squibb (1) · CSL Behring (1) · Cantonal Hospital of St. Gallen (1) · Celgene Corporation (1) · Center for Integrated Rehabilitation and Organ Failure Horn (1) · Centocor, Inc. (1) · Centre for Food and Nutrition Research, Yaounde (1) · Charite University, Berlin, Germany (1) · Charles Drew University of Medicine and Science (1) · Daiichi Sankyo (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · GTx (1)
United States (15) · India (5) · United Kingdom (5) · Canada (4) · Germany (4) · Poland (3) · Romania (3) · Australia (2) · Bangladesh (2) · Netherlands (2) · Switzerland (2) · Argentina (1) · Brazil (1) · Bulgaria (1) · Cameroon (1)
Abu Ahmed Shamim, MS (1) · Alain B Labrique, PhD (1) · Britta Schumacher, PhD (1) · Emiel FM Wouters, PhD, MD (1) · Florian Strasser, PD Dr. MD (1) · Gabriel Fox, MB BChir (1) · Gabriel Medoua Nama, Ph.D. (1) · Hasmot Ali, MPH (1) · Ihab Tewfik, PhD (1) · James A Berkley (1) · Jamie Hayden Von Roenn, MD (1)
PMID 17662149, PMID 18257397, PMID 18989154, PMID 21475692, PMID 23499390, PMID 25524795, PMID 27252077, PMID 27680994, PMID 28644348, PMID 30095981, PMID 30184222, PMID 30807589, PMID 31037340, PMID 31775877, PMID 32240304, PMID 32875267, PMID 33154417, PMID 34538239, PMID 36283827, PMID 38500292, PMID 38641716, PMID 39007915, PMID 39282907, PMID 39662676
2017 (1), 2023 (1), U10CA081920 (1)